ROR1 and non-small cell lung carcinoma: ROR1 chimeric antigen receptor-specific autologous T-lymphocytes (CAR-T) therapy is undergoing clinical trials in triple-negative breast cancers (TNBC) and non-small cell lung cancers (NSCLC)14,27.